Cardiac Risk
Cardiac Risk
Your heart is amazing. Not only is it your most critical organ but also one of the most hard-working. The average adult heart beats around 100,000 times a day, acting as a giant pump for all the blood in your body. Indeed, every day your heart pumps over nine litres of blood through a system of blood vessels over 60,000 miles long – it’s little wonder, then, the importance placed on looking after such a vital muscle.
Did you know?
Cardiovascular Diseases (CVDs) are the number 1 cause of death globally, more people die annually from CVDs than any other cause.
Over time, and influenced by lifestyle choices, the heart grows weaker, needing to work harder to fulfil its function. Crucial lifestyle changes now could limit your risk of developing serious cardiac conditions, such as Cardiovascular Disease (CVD) in the future.
While lifestyle changes may help to limit your risk of CVD, and related heart condition, it is impossible to eradicate it completely for everyone. Cardiovascular disease is the number one cause of death globally. Across the world, 17.7 million people died from CVDs in 2015. In the UK, it accounts for nearly one death around every eight minutes.
But early screening and improved access to cutting-edge diagnostics could lower this figure significantly. According to the WHO there are 8 key risk factors of developing CVD and they account for as much as 61% of all cardiovascular deaths, these include;
Smoking
The harmful substances in tobacco can damage and narrow blood vessels, causing CVDs. Smoking kills approximately half of persistent smokers, around 14% of deaths from circulatory disease can be attributed to smoking.
High Blood Pressure
High blood pressure (hypertension) is one of the most important risk factors of CVD, if your blood pressure is too high your blood vessels can become damaged.
High BMI
Being overweight or obese increases the risk of developing diabetes and high blood pressure, both of which can cause CVD. You’re at an increased risk of CVD if your BMI is 25 or above.
High Cholesterol
Cholesterol is a fatty substance found in the blood, high levels of cholesterol can cause blood vessels to narrow and increase the risk of developing a blood clot. Reducing the populations LDL-Cholesterol by 5% would prevent 64,000 cases of CVD.
Lack of Physical Activity
If you don’t exercise regularly, it’s more likely you’ll develop high blood pressure, high cholesterol levels and become overweight. All of which are risk factors of CVD. Exercising regularly helps to keep the heart healthy.
Other CVD risk factors include an excessive alcohol intake, an unhealthy diet and high levels of blood glucose.
Related Products
Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers many tests for the diagnosis and monitoring of cardiac diseases.
Cardiac Panel
| Cholesterol | CRP Full Range(0.3-160mg/l) | Direct LDL Cholesterol | sLDL |
| CK-MB | CRP High Sensitivity | Heart-Type Fatty Acid Binding Protein (H-FABP) | Triglycerides |
| CK-NAC | Digoxin | Lipoprotein(a) | TxB Cardio |
| CRP | Direct HDL Cholesterol | Myoglobin |
Our world leading test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Cardiac health and regular cardiovascular screening is important to enable risk factors to be detected in their earliest stages. Randox reagents offer a comprehensive cardiology product profile which includes high performance reagents for the detection of conventional risk factors, as well as emerging biomarkers associated with further risk.
sLDL cholesterol
sLDL cholesterol is a vital cardiac risk marker which utilises the “Denka Seiken” method which produces results in less than ten minutes. Research has shown individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction (MI), even for those who HDL, LDL, Total Cholesterol and Triglyceride levels are considered ‘normal’. Elevated levels of sLDL are associated with a sedentary lifestyle, a diet high in saturated fat, insulin resistance, pre-diabetes and genetic disposition. Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels reduce the risk of both CVD and MI.
For more information visit: www.randox.com/sldl-cholesterol/
Lipoprotein (a)
Lipoprotein (a) is a major independent genetic risk factor for premature CVD and elevated levels can occur in patients with otherwise normal lipid levels, therefore providing much needed information in relation to a patient’s risk of developing CVD.Along with other tests, Lp(a) can provide additional information on a patient’s risk factor of developing cardiovascular disease (CVD).
The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias providing more accurate and consistent results.
For more information visit: www.randox.com/lipoprotein-a/
HDL3 Cholesterol
HDL3 Cholesterol is a smaller and more dense sub fraction of the HDL particle. HDL comprises of several subclass particles, which differ in their sizes, densities and components. HDL is the scavenger of cholesterol within arterial walls and the levels of HDL3 is too low, the ability to remove this cholesterol is reduced. Therefore, it is widely accepted that there is an inverse correlation between HDL3 and cardiovascular disease risk.
For more information visit: https://www.randox.com/hdl3/
Cardiology and Lipid Testing Panel
- Apolipoprotein A-I
- Apolipoprotein A-II
- Apolipoprotein B
- Apolipoprotein C-II
- Apolipoprotein C-III
- Apolipoprotein E
- Cholesterol (sLDL)
- Cholesterol (HDL)
- Cholesterol (LDL)
- Cholesterol (Total)
- Cholesterol (HDL3)
- Lipoprotein (a)
- High sensitivity CRP
- Homocysteine
- Triglycerides
- HDL3-C
- sPLA₂-IIA
- Heart Type Fatty Acid Binding Protein (H-FABP)
- CK-MB
- Myoglobin
- Digoxin
- TxBCardio™
Browse our full cardiology and lipid testing panel here.
To request an application for your specific analyser, contact us at reagents@randox.com
When diagnosing and monitoring CVD, it is vital that laboratories have a robust Quality Control (QC) system in place to ensure the accuracy and reliability of the results produced. The Acusera Cardiac Controls have been designed to cover a wide range of cardiac markers at clinical decision levels eliminating the need for additional low level controls at extra expense. Available in both liquid ready-to-use and lyophilised formats, they are ideal for use at the point-of-care and in the laboratory. Manufactured from 100% human serum a matrix similar to that of the patient is guaranteed.
Liquid Cardiac Control
- Liquid ready-to-use
- 100% human serum
- Assayed target values provided for 8 cardiac markers
- Cut off levels for Troponin I and T in line with internationally recommended levels
- Stable to expiry date at 2°C – 8°C
- Open vial stability of 30 days at 2°C – 8°C for all analytes
Analytes
| Myoglobin | Troponin I | Troponin T |
| NT – ProBNP | CK-MB (Mass) | D-dimer |
| Digoxin | hsCRP |
Find out more about our Liquid Cardiac Quality Control here.
Other cardiac quality controls include:
For more information, visit our Cardiac Quality Controls page.
RIQAS Cardiac Programme
The RIQAS Cardiac EQA programme is designed to monitor the performance of up to 7 clinically significant cardiac markers. Two flexible reporting options are available to suit the needs of all laboratory sizes.
- Accredited to ISO/IEC 17043
- Lyophilised for enhanced stability
- 100% human serum
- Bi-weekly reporting
- Submit results and view reports online via RIQAS.Net
- Register up to five instruments at no extra cost
For more information, visit our RIQAS Cardiac Programme page.
Our Randox Health clinics offer comprehensive health testing as part of our Signature, Everyman and Everywoman packages to identify and assess risk of developing Cardiovascular Disease. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).
For more information visit: https://www.randoxhealth.com/
Obesity and Kidney Disease: What is the Connection?
30th January 2019
Obesity and Kidney Disease: What is the Connection?
The month of January has forever been the month of resolutions with many choosing to ditch the sweets and join the gym. However, for many these efforts are limited to January and bad habits are quick to remerge. Obesity has been a burden on the health service for many years with the problem, like many people’s waist lines, only continuing to expand.
Recent findings have shown that this problem is no longer just increasing in developed countries but also in developing countries. In fact, worldwide obesity has tripled since 1975. In 2016, more than 1.9 million adults were classed as overweight, of which over 650 million were obese.1 These are shocking statistics for a condition that is preventable. As a global concern, it is important to assess all the potential risks of this problem.
The most common diseases associated with obesity are cardiovascular disease (CVD) and diabetes. However, the associated risks are much greater than this. Being overweight may also increase the risk of certain types of cancer, sleep apnea, osteoarthritis, fatty liver disease and kidney disease.2
Obesity is now recognised as a potent risk factor for the development of renal disease.3 Excess weight has a direct impact on the development and progression of chronic kidney disease (CKD). Globally, the prevalence of diabetic kidney disease rose by 39.5% between 2005 and 2015, coinciding with the increased CKD prevalence.4 In obese individuals, the kidneys have to work harder, filtering more blood than normal to meet the metabolic demands of increased body weight, increasing the risk of kidney disease.
The traditional diagnostic test for renal impairment is creatinine. This test is carried out through the measurement of creatinine levels in the blood to assess the kidneys ability to clear creatinine from the body. This is called the creatinine clearance rate which helps to estimate the glomerular filtration rate (GFR), which is the rate of blood flow through the kidneys.5
Problems arise when using creatinine for CKD testing as a number of factors need to be taken into consideration including age, gender, ethnicity and muscle mass. For this reason, black men and women exhibit higher creatinine levels than white men and women, raising concern over the accuracy of this test for certain patient groups.6 In addition, serum creatinine is not an adequate screening test for renal impairment in the elderly due to their decreased muscle mass.7
The main disadvantage of using creatinine to screen for renal impairment is that up to 50% of renal function can be lost before significant creatinine levels become detectable as creatinine is insensitive to small changes in GFR. Consequently, treatment is not provided at the appropriate time which can be fatal, therefore, an earlier and more sensitive marker for renal function is vital.8
These disadvantages have not only been highlighted in research but also by the national institute for health and care excellence (NICE). NICE updated the classification of CKD in 2004 to include the albumin: creatinine ratio (ACR). They split chronic kidney disease patients into categories based on GFR and ACR. Figure 1 highlights the different categories and risk of adverse outcomes. NICE recommend using eGFR Cystatin C for people in the CKD G3aA1 and higher.9
Figure 1 Classification of Chronic Kidney Disease using GFR and ACR categories.9
Despite these suggestions, Creatinine is still being used for G3a1 and increasing risk levels.
The utility of cystatin C as a diagnostic biomarker for kidney disease has been documented to show superiority of traditional CKD tests. There is no ‘blind area’ making it very sensitive to small changes in GFR and capable of detecting early reductions. Furthermore, this marker is less influenced by diet or muscle mass and has proven to be a beneficial test in patients who are overweight.8
A number of studies support the statement: ‘Cystatin C levels are higher in overweight and obese patients’. This is important because when cystatin c levels are too high, it may suggest that the kidneys are not functioning properly. One study conducted, using a nationally representative sample of participants, found that overweight and obesity maintained a strong association with elevated serum cystatin C. This suggests that weight can affect the levels of cystatin C and therefore the likelihood of developing kidney disease.10
How Randox can Help
The Randox automated Latex Enhanced Immunoturbidimetric Cystatin C tests offers an improved method for assessing CKD risk, combined with a convenient format for routine clinical use, for the early assessment of at risk patients. Randox is currently one of the only diagnostic manufacturers who offer an automated biochemistry test for Cystatin C measurement, worldwide.
Want to know more?
Contact us or visit our featured reagent page to learn more.
Related Products
Randox Reagents
Resource Hub
References
- World Health Organization. Obesity and Overweight . int. [Online] WHO. [Cited: January 22, 2019.] https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
- Health Risks of Being Overweight. NIDDK. [Online] National Institute of Diabetes and Digestive and Kidney Diseases. [Cited: March 24, 2019.] https://www.niddk.nih.gov/health-information/weight-management/health-risks-overweight.
- Kidney Health Australia . Obesity and Chronic Kidney Disease: The Hidden Impact. Kidney Health Week/ World Kidney Day 2017. [Online] Kidney Health Australia. [Cited: January 22, 2019.] https://kidney.org.au/cms_uploads/docs/kidney-health-australia-report-obesity-and-chronic-kidney-disease–the-hidden-impact_06.03.17.pdf.
- Neuen, Brendon Lange, et al. Chronic kidney disease and the global NCDs agenda. s.l. : BMJ Global Health, 2017
- Creatinine and Creatinine Clearance Blood Tests. WebMD. [Online] WebMD. [Cited: January 22, 2019.] https://www.webmd.com/a-to-z-guides/creatinine-and-creatinine-clearance-blood-tests#1.
- Lascano, Martin E and Poggio, Emilio D. Kidney Function Assessment by Creatinine-Based Estimation Equations. Cleveland Clinic. [Online] August 2010. [Cited: 16 May 2018.] http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/kidneyfunction/.
- Swedko, Peter J, et al. Serum Creatinine Is an Inadequate Screening Test for Renal Failure in Elderly Patients. Research Gate. [Online] February 2003. [Cited: 6 May 2018.] https://www.researchgate.net/publication/8243393_Serum_Creatinine_Is_an_Inadequate_ Screening_Test_for_Renal_Failure_in_Elderly_Patients.
- Mishra, Umashankar. New technique developed to detect chronic kidney disease. Business Line. [Online] 07 May 2018. [Cited: 17 May 2018.] https://www.thehindubusinessline.com/news/science/new-technique-to-detect-chronic-kidney-disease/article23803316.ece.
- National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management: 1 Recommendations. National Institute for Health and Care Excellence. [Online] January 2015. https://www.nice.org.uk/guidance/cg182/chapter/1- recommendations#classification-of-chronic-kidney-disease-2.
- Overweight and Obesity and Elevated Serum Cystatin C Levels in US Adults . Muntner, Paul, et al. 4, s.l. : NCBI, 2008, Vol. 121.
NeoNatal
Metabolic health is a term used to describe a collection of required chemical reactions that take place in all living organisms. A metabolic disorder develops when an abnormal chemical reaction occurs which alters the normal metabolic process.
Did you know?
Approximately 20-25% of the world’s adult population have metabolic syndrome?
Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers several parameters to assess your overall metabolic health.
Metabolic Health Profile
| Albumin | Chloride | Potassium |
| Alkaline Phosphatase | C02 Total | Sodium |
| ALT | Creatinine | Total Bilirubin |
| AST (GOT) | Glucose | Total Protein |
| Direct Bilirubin | Lactate | Urea |
| Calcium |
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.Our world-famous test menu of high quality reagents ensures excellence in patient care, guaranteeing unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Metabolic syndrome comprises of risk factors such as high blood pressure, high blood sugar/cholesterol and abdominal fat, which together, can lead to serious long term problems including an increased risk of heart disease, stroke and developing type 2 diabetes. Randox have developed an extensive range of reagents to accurately diagnose and monitor metabolic health, with the aim that patients can take the appropriate measurements to improve their health.
All reagents are available for use on a wide range of third party biochemistry analysers. Contact us to request an application for your specific analyser.
Adiponectin
Adiponectin is a clinical diagnostic biomarker for metabolic risk assessment. Adiponectin is solely excreted by adipocytes and is a protein hormone with anti-inflammatory and insulin-sensitising properties. It plays an important role in a number of metabolic processes such as glucose regulation and fatty acid oxidation. Levels of adiponectin have been linked with several pathologies including metabolic syndrome, cancer and cardiovascular disease, as levels are inversely correlated with Abdominal Visceral Fat (AVF). Randox is one of the only manufacturers of adiponectin in an automated biochemistry format, removing the inconvenience and time consumption associated with traditional ELISA-based testing.
For more information visit: https://www.randox.com/adiponectin/
Small-dense LDL (sLDL) Cholesterol
Small-dense LDL cholesterol is a vital cardiac risk marker, usually tested in patients with prediabetes or metabolic syndrome. Randox sLDL utilises the “Denka Seiken” method which produces results in less than ten minutes. Research has shown individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction (MI), even for those who HDL, LDL, Total Cholesterol and Triglyceride levels are considered ‘normal’. Elevated levels of sLDL are associated with a sedentary lifestyle, a diet high in saturated fat, insulin resistance, pre-diabetes and genetic disposition. Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels reduce the risk of both CVD and MI.
For more information visit: www.randox.com/sldl-cholesterol/
TxBCardio™
Randox TxBCardio™ is used to assess the level of aspirin resistance in patients at risk of cardiovascular disease. Aspirin resistance is a serious clinical problem and is estimated to affect 25-20% of patients on a low dosage. It is important to assess aspirin resistance as this may be anticipated in patients with metabolic syndrome. The identification of these patients can be significantly improved through the use of Randox TxBCardio™ as the results generated can be used to enable timely intervention by clinicians and they can focus on anti-platelet therapy.
For more information visit: https://www.randox.com/txbcardio/
Other metabolic health tests:
- Albumin
- Alkaline Phosphatase
- ALT
- AST (GOT)
- Direct Bilirubin
- Calcium
- Chloride
- CO2 Total
- Creatinine
- Glucose
- Lactate
- Potassium
- Sodium
- Total Bilirubin
- Total Protein
- Urea
When diagnosing and monitoring metabolic-related complications such as Diabetes and Cardiovascular Disease (CVD), it is vital that laboratories have a robust Quality Control (QC) system in place to ensure the accuracy and reliability of the results produced. As a world leading manufacturer of QC solutions including Third Party Controls and External Quality Assessment (EQA), our extensive product portfolio is designed to help reduce costs and time without compromising on quality.
Diabetes
Liquid HbA1c Control
- Liquid ready-to-use format ideal for use in the lab or at the POC
- Whole blood sample matrix commutable with that of the patient sample
- Assayed control with values available for HPLC
- Convenient bi-level pack accurately covering the patient reportable range
- Open vial stability of 30 days ultimately helping to reduce waste and costs
- For more information visit: https://www.randox.com/liquid-hba1c-quality-control/
Glycated Hemoglobin EQA Programme
- Monthly analysis ensuring early identification of test system errors
- Maximised peer groups for comparative performance assessment
- Reports available within 72 hours allowing corrective action to be taken immediately
- User-friendly reports delivering at-a-glance performance assessment
- For more information visit: https://www.randox.com/hba1c-eqa/
CVD risk
Lipid Control
- Covers the complete lipid profile
- True third party control ensuring unbiased performance assessment with any instrument or method
- Manufactured from 100% human serum ensuring a matrix commutable with the patient sample
- Free from Sodium Azide which can interfere with direct clearance methods of HDL and LDL Cholesterol
- Three clinically significant levels available covering low, borderline and high risk levels of HDL and LDL Cholesterol
- For more information visit: https://www.randox.com/lipid-quality-control/
- Covers the complete lipid profile with a choice of reporting just three parameters at a reduced cost
- Monthly analysis ensuring early identification of test system errors
- Maximised peer groups for comparative performance assessment
- Reports available within 72 hours allowing corrective action to be taken immediately
- User-friendly reports delivering at-a-glance performance assessment
- For more information visit: https://www.randox.com/lipids-eqa/
Our Randox Health clinics offer comprehensive health testing as part of our Signature, Everyman and Everywoman packages to give you a comprehensive picture of your overall metabolic health. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).
For more information visit: https://www.randoxhealth.com/
A common misconception surrounding metabolic health is that it refers solely to your weight, and if you are overweight you are considered to be unhealthy. But in actual fact this may not be entirely true. Good metabolism means that your body is in good overall health, which doesn’t account for just your weight! Common metabolic disorders include genetic metabolic disorders, diabetes and metabolic syndrome. Understanding and testing to see how well your metabolism is functioning is key to ensuring long lasting health.
Genetics
There are a number of genetic metabolic disorders caused by mutations of single genes. Examples of common disorders include Gaucher’s disease, hemochromatosis and cystic fibrosis. Gaucher’s disease is a genetic disorder that affects the body’s ability to break down fat that can accumulate in the liver/spleen and bone marrow. Hemochromatosis is a condition that is caused by the over-absorption and build-up of iron while cystic fibrosis is a metabolic disorder that appears as a result of a build-up of mucus in lungs/liver and intestines. Each of these metabolic disorders affect certain organs from functioning properly and therefore your overall healthiness.
Diabetes
Type 2 diabetes is one of the most common types of metabolic disorders in the world that is expected to affect 592 million people by 2035. It is characterised by high blood sugar, insulin resistance or a lack of insulin being produced by the pancreas. Insulin resistance occurs when the body isn’t able to use insulin the right way which increases blood glucose levels. Insulin is needed for cells to take in glucose (sugar) from the bloodstream and convert it into energy. Over time this lack of insulin can damage the organs in your body.
Metabolic Syndrome
Metabolic syndrome (also known as syndrome X, Reaven’s syndrome, and CHAOS) is not a disease but a collection of risk factors that affect your health; these include high blood pressure, high blood sugar/cholesterol and abdominal fat. Left untreated, these risk factors, together, can lead to long term serious problems including an increased risk of heart disease, stroke and developing type 2 diabetes.
Can you improve your metabolic health?
Yes! The good news is that if you discover that your metabolic health is not up to scratch you can improve it through a combination of diet, exercise and lifestyle adjustments such as:
- 30 minutes of moderate to intense exercise 5-7 times a week
- Low-dose aspirin to reduce your risk of stroke or heart attack
- Quit smoking
- Medication for blood pressure/cholesterol/ blood sugar
- Limit alcohol intake
- Eat a healthy balanced diet
Related Products
Metabolic Health
Metabolic health is a term used to describe a collection of required chemical reactions that take place in all living organisms. A metabolic disorder develops when an abnormal chemical reaction occurs which alters the normal metabolic process.
Did you know?
Approximately 20-25% of the world’s adult population have metabolic syndrome?
A common misconception surrounding metabolic health is that it refers solely to your weight, and if you are overweight you are considered to be unhealthy. But in actual fact this may not be entirely true. Good metabolism means that your body is in good overall health, which doesn’t account for just your weight! Common metabolic disorders include genetic metabolic disorders, diabetes and metabolic syndrome. Understanding and testing to see how well your metabolism is functioning is key to ensuring long lasting health.
Genetics
There are a number of genetic metabolic disorders caused by mutations of single genes. Examples of common disorders include Gaucher’s disease, hemochromatosis and cystic fibrosis. Gaucher’s disease is a genetic disorder that affects the body’s ability to break down fat that can accumulate in the liver/spleen and bone marrow. Hemochromatosis is a condition that is caused by the over-absorption and build-up of iron while cystic fibrosis is a metabolic disorder that appears as a result of a build-up of mucus in lungs/liver and intestines. Each of these metabolic disorders affect certain organs from functioning properly and therefore your overall healthiness.
Diabetes
Type 2 diabetes is one of the most common types of metabolic disorders in the world that is expected to affect 592 million people by 2035. It is characterised by high blood sugar, insulin resistance or a lack of insulin being produced by the pancreas. Insulin resistance occurs when the body isn’t able to use insulin the right way which increases blood glucose levels. Insulin is needed for cells to take in glucose (sugar) from the bloodstream and convert it into energy. Over time this lack of insulin can damage the organs in your body.
Metabolic Syndrome
Metabolic syndrome (also known as syndrome X, Reaven’s syndrome, and CHAOS) is not a disease but a collection of risk factors that affect your health; these include high blood pressure, high blood sugar/cholesterol and abdominal fat. Left untreated, these risk factors, together, can lead to long term serious problems including an increased risk of heart disease, stroke and developing type 2 diabetes.
Can you improve your metabolic health?
Yes! The good news is that if you discover that your metabolic health is not up to scratch you can improve it through a combination of diet, exercise and lifestyle adjustments such as:
- 30 minutes of moderate to intense exercise 5-7 times a week
- Low-dose aspirin to reduce your risk of stroke or heart attack
- Quit smoking
- Medication for blood pressure/cholesterol/ blood sugar
- Limit alcohol intake
- Eat a healthy balanced diet
Related Products
Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers several parameters to assess your overall metabolic health.
Metabolic Health Profile
| Albumin | Chloride | Potassium |
| Alkaline Phosphatase | C02 Total | Sodium |
| ALT | Creatinine | Total Bilirubin |
| AST (GOT) | Glucose | Total Protein |
| Direct Bilirubin | Lactate | Urea |
| Calcium |
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.Our world-famous test menu of high quality reagents ensures excellence in patient care, guaranteeing unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Metabolic syndrome comprises of risk factors such as high blood pressure, high blood sugar/cholesterol and abdominal fat, which together, can lead to serious long term problems including an increased risk of heart disease, stroke and developing type 2 diabetes. Randox have developed an extensive range of reagents to accurately diagnose and monitor metabolic health, with the aim that patients can take the appropriate measurements to improve their health.
All reagents are available for use on a wide range of third party biochemistry analysers. Contact us to request an application for your specific analyser.
Adiponectin
Adiponectin is a clinical diagnostic biomarker for metabolic risk assessment. Adiponectin is solely excreted by adipocytes and is a protein hormone with anti-inflammatory and insulin-sensitising properties. It plays an important role in a number of metabolic processes such as glucose regulation and fatty acid oxidation. Levels of adiponectin have been linked with several pathologies including metabolic syndrome, cancer and cardiovascular disease, as levels are inversely correlated with Abdominal Visceral Fat (AVF). Randox is one of the only manufacturers of adiponectin in an automated biochemistry format, removing the inconvenience and time consumption associated with traditional ELISA-based testing.
For more information visit: https://www.randox.com/adiponectin/
Small-dense LDL (sLDL) Cholesterol
Small-dense LDL cholesterol is a vital cardiac risk marker, usually tested in patients with prediabetes or metabolic syndrome. Randox sLDL utilises the “Denka Seiken” method which produces results in less than ten minutes. Research has shown individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction (MI), even for those who HDL, LDL, Total Cholesterol and Triglyceride levels are considered ‘normal’. Elevated levels of sLDL are associated with a sedentary lifestyle, a diet high in saturated fat, insulin resistance, pre-diabetes and genetic disposition. Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels reduce the risk of both CVD and MI.
For more information visit: www.randox.com/sldl-cholesterol/
TxBCardio™
Randox TxBCardio™ is used to assess the level of aspirin resistance in patients at risk of cardiovascular disease. Aspirin resistance is a serious clinical problem and is estimated to affect 25-20% of patients on a low dosage. It is important to assess aspirin resistance as this may be anticipated in patients with metabolic syndrome. The identification of these patients can be significantly improved through the use of Randox TxBCardio™ as the results generated can be used to enable timely intervention by clinicians and they can focus on anti-platelet therapy.
For more information visit: https://www.randox.com/txbcardio/
Other metabolic health tests:
- Albumin
- Alkaline Phosphatase
- ALT
- AST (GOT)
- Direct Bilirubin
- Calcium
- Chloride
- CO2 Total
- Creatinine
- Glucose
- Lactate
- Potassium
- Sodium
- Total Bilirubin
- Total Protein
- Urea
When diagnosing and monitoring metabolic-related complications such as Diabetes and Cardiovascular Disease (CVD), it is vital that laboratories have a robust Quality Control (QC) system in place to ensure the accuracy and reliability of the results produced. As a world leading manufacturer of QC solutions including Third Party Controls and External Quality Assessment (EQA), our extensive product portfolio is designed to help reduce costs and time without compromising on quality.
Diabetes
Liquid HbA1c Control
- Liquid ready-to-use format ideal for use in the lab or at the POC
- Whole blood sample matrix commutable with that of the patient sample
- Assayed control with values available for HPLC
- Convenient bi-level pack accurately covering the patient reportable range
- Open vial stability of 30 days ultimately helping to reduce waste and costs
- For more information visit: https://www.randox.com/liquid-hba1c-quality-control/
Glycated Hemoglobin EQA Programme
- Monthly analysis ensuring early identification of test system errors
- Maximised peer groups for comparative performance assessment
- Reports available within 72 hours allowing corrective action to be taken immediately
- User-friendly reports delivering at-a-glance performance assessment
- For more information visit: https://www.randox.com/hba1c-eqa/
CVD risk
Lipid Control
- Covers the complete lipid profile
- True third party control ensuring unbiased performance assessment with any instrument or method
- Manufactured from 100% human serum ensuring a matrix commutable with the patient sample
- Free from Sodium Azide which can interfere with direct clearance methods of HDL and LDL Cholesterol
- Three clinically significant levels available covering low, borderline and high risk levels of HDL and LDL Cholesterol
- For more information visit: https://www.randox.com/lipid-quality-control/
- Covers the complete lipid profile with a choice of reporting just three parameters at a reduced cost
- Monthly analysis ensuring early identification of test system errors
- Maximised peer groups for comparative performance assessment
- Reports available within 72 hours allowing corrective action to be taken immediately
- User-friendly reports delivering at-a-glance performance assessment
- For more information visit: https://www.randox.com/lipids-eqa/
Our Randox Health clinics offer comprehensive health testing as part of our Signature, Everyman and Everywoman packages to give you a comprehensive picture of your overall metabolic health. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).
For more information visit: https://www.randoxhealth.com/
Renal Function and Health
Your kidneys are vital for survival, they filter waste substances out of your blood and balance the levels of salts and water in our bodies. Your kidneys filter around 180 litres of blood every day, control the production of red blood cells and release hormones that regulate blood pressure – it’s little wonder, then, the importance placed on looking after such a vital organ.
Did you know?
Around 1 in 8 people in the UK will develop Chronic Kidney Disease (CKD)
Kidney Disease can affect people of all ages and races, 10% of the population worldwide is affected by Chronic Kidney Disease (CKD.) Since Kidney Disease can sneak up without symptoms it has been labelled a silent killer, a person can lose up to 90% of their kidney function before experiencing any signs or symptoms.
As kidney disease gets worse, wastes can build up in your blood and make you feel sick. You may develop additional problems such as high blood pressure, anemia, weak bones, poor nutritional health and nerve damage. Kidney disease also increases your risk of developing heart or blood vessel disease. These problems often develop slowly and will often lead to kidney failure.
The two main causes of CKD are diabetes and high blood pressure, which are responsible for up to two-thirds of cases, other causes include inherited kidney diseases and malformations at birth.
How is Chronic Kidney Disease detected?
Early detection and treatment is crucial to keep kidney disease from developing into kidney failure, some simple tests can be carried out to detect early kidney disease. These are;
- A urine test to check if there is any protein present
- A blood test to measure levels of creatinine
The best treatment is early detection when CKD can be slowed or stopped, however once kidneys fail, treatment with dialysis or a kidney transplant is needed. 8 of 10 people on the transplant list are waiting for a kidney, the average wait for a new kidney is 3 years, and every day one kidney patient will die waiting for a transplant.
Reduce your risk of developing CKD
Your kidneys are vital to your overall health, so it’s important to look after them. There are 5 simple steps that can help you keep them in good shape;
- Stay hydrated
- Maintain a balanced diet and keep your weight in check
- Monitor your blood pressure
- Quit Smoking
- Limit your alcohol intake
Related Products
Randox has developed the RX series of clinical chemistry analysers for superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers several parameters to assess renal health.
Renal Function
| Albumin | Creatinine Enzymatic | IgG | Phosphorus (Inorganic) |
| Ammonia | Creatinine (Jaffe) | LDH | Urinary Protein |
| Beta-2 Microglobulin | Cystatin C | Magnesium | Urea |
| Calcium | Glucose | Potassium | Uric Acid |
| Chloride | HbA1c/Hb | Sodium | |
Our world-famous test menu of high quality reagents ensures excellence in patient care, guaranteeing unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Kidney disorders can develop and advance overtime without any signs and the symptoms are not recognised as being associated with renal impairment. Kidney health and regular renal screening is important to enable renal impairment to be detected in its earliest stages to prevent renal failure. Randox offers a comprehensive range of high performance reagents for the detection and characterisation of renal function problems.
All reagents are available for use on a wide range of third party biochemistry analysers. Contact us to request an application for your specific analyser.
Cystatin C
Cystatin C is a useful marker where creatinine measurements are unsuitable e.g. patients who are obese, malnourished, have liver cirrhosis or reduced muscle mass. Cystatin C also does not have a ‘blind area’ unlike creatinine – up to 50% of renal function can be lost before sufficient creatinine levels are detectable. Cystatin C is extremely sensitive to small changes in Glomerular Filtration Rate (GFR) and so is capable of detecting early stages of renal impairment.
For more information on Cystatin C, visit: www.randox.com/cystatin-c
Enzymatic Creatinine
Creatinine clearance in the kidneys gives a measurement of the GFR which is the standard marker for renal function. The enzymatic method offers superior specificity when compared to the traditional Jaffe method. Other benefits of the enzymatic method over the Jaffe method includes: limited interferences from bilirubin, haemoglobin, Intralipid® and Triglycerides making the assay more suitable for neonatal samples, eliminates the need for urea determination, highly specific and does not overestimate serum creatinine.
For more information on Enzymatic Creatinine, visit: www.randox.com/creatinine
Microalbumin
The detection of albumin in urine can be an indicator of kidney injury, as damage to the glomerular basement membrane results in albumin seeping out of the kidneys into urine. Sustained elevations of urinary albumin concentrations are called Microalbuminuria. The Randox Microalbumin test is an excellent marker of kidney disease and can identify individuals with diabetic nephropathy approximately 5-10 years earlier than proteinuria tests reducing the incidence of end stage renal disease. The American Diabetes Association and Diabetes UK recommend that all diabetics are screened for microalbuminuria on a yearly basis.
For more information on Microalbumin, visit: www.randox.com/microalbumin
Renal Testing Panel
- Cystatin C
- Creatinine Enzymatic
- Creatinine Jaffe
- Microalbumin
- Total Urinary Protein
- Urea
- Sodium
- Potassium
- Albumin
- Ammonia
- β₂ Microglobulin
- Calcium
- Chloride
- Glucose
- HbA1c
- IgG
- LDH
- Magnesium
- Phosphorus (Inorganic)
- Uric Acid
When diagnosing and monitoring Chronic Kidney Disease (CKD), it is vital that laboratories have a robust Quality Control (QC) system in place to ensure the accuracy and reliability of the results produced. The Acusera Chemistry and Urine Controls have been designed to cover a wide range of kidney function tests at clinical decision levels eliminating the need for additional low level controls at extra expense.
Our range of Chemistry Controls contain up to 100 analytes and cover a wide range of kidney function tests. Available in a choice of liquid or lyophilised formats, options are available to suit all laboratory sizes and budgets.
Our portfolio of Urine Controls cover the full range of clinical testing, manufactured from 100% human serum a matrix similar to that of the patient is guaranteed. They are available in both liquid ready-to-use and lyophilised formats, making them ideal for use at the point-of-care and in the laboratory.
Common kidney function parameters we cover include;
- Albumin
- Urea/BUN
- Bicarbonate
- Calcium
- Chloride
- Creatinine
- Creatinine Clearance
- Cystatin C
- Glucose
- Phosphate
- Potassium
- Sodium
- Urine Albumin
- Albumin/Creatinine Ratio
- Beta-2 Microglobulin
- Urinalysis
- Urine Protein
For more information, contact us at acusera@randox.com
We also have corresponding RIQAS Chemistry and Urine Programmes which cover the common kidney function tests, including;
RIQAS General Clinical Chemistry Programme
The RIQAS General Clinical Chemistry EQA programme is designed to monitor the performance of up to 52 parameters. Three flexible yet cost effective programme options are available.
- Accredited to ISO/IEC 17043
- Lyophilised for enhanced stability
- Human based serum
- Bi-weekly reporting
- Submit results and view reports online via RIQAS.Net
- Register up to five instruments at no extra cost
- Reference method values are provided for selected parameters/lots
For more information, visit our RIQAS General Clinical Chemistry Programme page.
RIQAS Human Urine Programme
The RIQAS Human Urine EQA programme is designed to monitor the performance of up to 25 routine chemistry assays in urine.
- Accredited to ISO/IEC 17043
- Lyophilised for enhanced stability
- 100% human urine
- Bi-weekly reporting
- Submit results and view reports online via RIQAS.Net
- Register up to five instruments at no extra cost
For more information, visit our RIQAS Human Urine Programme page
Our Randox Health clinics offer comprehensive health testing as part of our Signature, Everyman and Everywoman packages to identify and assess risk of developing Kidney Disease. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).
For more information visit: https://www.randoxhealth.com/
Randox Liver Health
The liver is responsible for many critical functions within the body and should it become diseased or injured, the loss of those functions can cause significant damage to the body. Randox are focusing on liver health, we will look at liver disease, its main causes and how to reduce your risk of many types of liver disease with some simple lifestyle changes.
Did you know?
One in five of us is at risk of developing liver damage!
Liver disease is now the fifth largest cause of death, with as many as 1 in 10 people experiencing problems with their liver at sometime in their life. Liver diseases are extremely costly in terms of human suffering, general practitioner and hospital visits, and premature loss of productivity. Most people with liver disease die in working age (16-85 years) making liver disease the third biggest cause of premature mortality, mortality rates for liver disease have increased 400% since 1970.
The three main causes of liver disease are;
1. Alcohol-related liver disease (ALD)
Regularly drinking more than the recommended amount of alcohol over a long period of time can damage your liver, leading to alcohol-related liver disease (ALD) and liver cancer. Overall, alcohol-related liver disease accounts for well over a third (37%) of liver disease deaths. More than 1 in 10 deaths of people in their 40’s are due to liver disease, with the vast majority from alcohol-related liver disease.
2. Non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease is caused by a build up of fatty deposits in the liver, causing inflammation and scarring. After years of inflammation NAFLD leads to cirrhosis causing the liver to become scarred and lumpy; this damage is permanent and ultimately can lead to liver failure and/or cancer.
NAFLD is more common in those who are overweight or obese. A healthy liver should contain little or no fat, it is estimated that 1 in every 3 people in the UK have early stages of NAFLD due to small amounts of fats in the liver.
As well as being overweight, you are also at an increased risk of developing NAFLD if you have: type 2 diabetes, high blood pressure and/or high cholesterol.
3. Hepatitis
Hepatitis refers to an inflammatory condition of the liver. It’s commonly caused by a viral infection, viral hepatitis affects over 700,00 people in the UK. Most people can recover from hepatitis A with no lasting liver damage, but hepatitis B and C can cause long term liver damage and liver cancer.
Hepatitis can lead to severe liver damage including cirrhosis, increasing the risk of liver cancer.
Related Products
Hepatic Function
| Albumin | Complement Component 3 | IgG | Transthyretin (Prealbumin) |
| Aldolase | Complement Component 4 | IgM | Bile Acids |
| Alkaline Phosphatase | Direct Bilirubin | Iron (UIBC) | |
| Alpha-I Antitrypsin | Gamma GT | LAP | |
| ALT | GLDH | LDH | |
| Ammonia | Glycerol | Total Bilirubin | |
| AST (GOT) | Haptoglobin | Total Protein | |
| Cholinesterase | IgA | Transferrin |
Our world leading test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.
For more information visit: https://www.randox.com/clinical-chemistry-analysers/
Randox supply a range of third party clinical diagnostic reagents to aid in the diagnosis of various liver diseases, and for managing the complications of such diseases. All reagents are available for use on a range of third party biochemistry analysers. Contact us to request an application for your specific analyser.
Unique tests from Randox
5th Generation Bile Acids
- Bile acids is a highly sensitive marker of liver function, enabling early and accurate diagnosis of liver disease. Bile acids is also the most accurate method for diagnosing obstetric cholestasis in pregnant women, a common liver condition affecting women during the second and third trimester of pregnancy.
- The fifth Generation Randox Total Bile Acids assay uses liquid stable two shot reagents in an enzymatic colorimetric assay for the quantitative in vitro determination of Bile Acids in serum or EDTA Heparinized plasma. The assay incorporates a more complex enzyme cycling mechanism than previous generations to amplify the signal, improving sensitivity and precision and reducing interference in haemolytic and lipaemic samples.
- For more information visit https://www.randox.com/bile-acids/
Vanadate Oxidation Bilirubin
- Bilirubin levels are important during the process of diagnosing and monitoring liver diseases including hepatitis, cirrhosis and gallstones. Other conditions characterised by elevated bilirubin concentrations include haemolytic anaemia and sickle cell disease.
- Randox Bilirubin adopts the superior vanadate oxidation methodology which unlike diazo-based methods, does not suffer from interference from unconjugated bilirubin, giving more accurate results.
- For more information visit https://www.randox.com/bilirubin/
Further testing panels from Randox
Hepatic Panel
When diagnosing and monitoring liver disease, it is vital that laboratories have a robust Quality Control (QC) system in place to ensure the accuracy and reliability of the results produced. As a world leading manufacturer of QC solutions including Third Party Controls and External Quality Assessment (EQA), our extensive product portfolio is designed to help reduce costs and time without compromising on quality.
Clinical Chemistry Controls
Our Acusera Clinical Chemistry Controls deliver effective consolidation and cost savings, covering the complete liver function panel;
- Total Serum Proteins
- Albumin
- Direct Bilirubin
- Alkaline Phosphatase
- AST
- ALT
Available in a choice of assayed/unassayed, liquid/lyophilised, premium/premium plus and human/bovine formats, options are available to suit all laboratory sizes and budgets. Find out more visit https://www.randox.com/clinical-chemistry-quality-controls/
RIQAS Clinical Chemistry Programme
Our RIQAS Clinical Chemistry Programme also covers the complete liver function panel at robust reference levels, challenging the full test system.
- Accredited to ISO/IEC 17043
- Lyophilised for enhanced stability
- Human based serum
- Bi-weekly reporting
- Submit results and view reports online via RIQAS.Net
- Register up to five instruments at no extra cost
- Reference method values are provided for selected parameters / lots
- Find out more visit https://www.randox.com/clinical-chemistry-eqa/
The RIQAS HIV/Hepatitis EQA programme is designed to monitor the performance of tests used to detect HIV/Hepatitis virus antibodies. All samples are conveniently supplied liquid ready-to-use and are suitable for qualitative methods of analysis.
- Liquid ready-to-use
- 100% human plasma
- Quarterly reporting (5 samples per quarterly distribution)
- Submit results and view reports online via RIQAS.Net
- Suitable for both quantitative and qualitative methods of analysis
- Find out more visit https://www.randox.com/hiv-hepatitis-eqa/
*Not accredited to ISO/IEC 17043
Our Randox Health clinics offer comprehensive health testing as part of our Signature package to identify and assess risk of developing liver disease. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).
For more information visit: https://www.randoxhealth.com/
Obesity: the disease, the problems, and the power of prevention
Earlier this year the World Obesity Federation made the stark statement that: “The early diagnosis and treatment of childhood obesity could be considered similar to vaccination.”
Essentially, they want to see this condition treated in the same way as chicken pox, measles and mumps: tackled – in the hope of eradication – by a strategic approach founded on proactive policies and early prevention.
Obesity in children and adolescents has risen tenfold in the last 40 years, according to a recent study by The Lancet. In Britain, one in ten young people aged between 5 and 19 is obese. Worryingly, the prevalence of obesity is actually higher in younger children than older ones.
The WHO first called for obesity to be understood as a disease in 1948, but back then it wasn’t even considered a risk factor for cardiovascular disease. In 1997 the WHO held a special conference on obesity and stated that: “the global epidemic projections for the next decade are so serious that public health action is urgently required.”
Then it was alarmed that the prevalence of men with a BMI greater than 30 was 15% and 16.5% in women. To think that it has now risen dramatically to 67% for men and 57% for women, highlights just how serious a problem obesity poses to society.
The calls for more countries to officially recognise it as a disease is based on the position that obesity meets the definition of a chronic, relapsing, progressive disease that causes organ damage.
Women and men who are obese are 12.5 and 5.2 times (respectively) more likely to develop diabetes than people who are a healthy weight. 90% of people with Type 2 diabetes are obese.
People with diabetes are then at a greater risk of a range of chronic health conditions including cardiovascular disease, blindness, amputation, kidney disease and depression than people without diabetes. Diabetes leads to a two-fold excess risk for cardiovascular disease, and diabetic retinopathy is the leading cause of preventable sight loss among people of working age in England and Wales. About one in twenty people have diabetes, yet people with diabetes account for one quarter to one third of hospital admissions for cardiovascular disease.
According to Government figures released this year, people who have Type 2 diabetes are 28.4% more likely to die early than their peers.
Getting in front of this wave of diabetes will not only bring down the numbers of people affected but also see a positive impact on the numbers of obese people. As with all conditions – the earlier they are identified, the better. To do this, new methods of diagnosis are being developed.
A radical new test for a protein found in our blood called adiponectin can identify pre-diabetes. This is a game-changing diagnostic tool that empowers people with the knowledge that they are at risk, but may be able to avoid it through relatively simple lifestyle changes.
The adiponectin test is available from Randox – both for clinical use and also through our Randox Health clinics. We have developed the most comprehensive health checks available on the market. These are so sensitive that in a range of conditions including diabetes we are able to identify signs of pre-illness. This enables clients to make often simple changes to stay healthy.
We know that prevention works. The NHS carried out a study in 2016 which revealed an average 26% reduction in new cases of Type 2 diabetes in those participating in a diabetes prevention programme, compared with usual care.
To find out more, click here.
For further information please email: randoxpr@randox.com
The Global Burden of Obesity
Obesity is a condition where a person has abnormal or excessive fat accumulation that presents a serious risk to health. This December, Randox are highlighting the health implications of this potentially deadly condition, especially throughout the midst of this festive season when it is all too easy to overindulge in fatty foods and sugary treats!
Worldwide obesity has almost tripled between 1975 and 2016, with over 650 million adults and 340 million children being recorded as obese in 2016 alone, highlighting that the prevalence of the condition is rapidly rising. Randox are dedicated to improving health and increasing the awareness and prevention of obesity and its consequences.
What are the causes and consequences of obesity?
With more people around the world adopting sedentary lifestyles and the increasing consumption of foods high in sugar and fat, there is a higher risk of an energy imbalance between calories consumed and calories expended, which is the fundamental cause of obesity. This increases the risk of a number of diseases such as cardiovascular disease, diabetes, musculoskeletal disease and some forms of cancer, with each condition having detrimental effects to your health.
One of the more serious consequences of obesity is type 2 diabetes mellitus (T2DM), where a resistance to insulin is developed causing blood sugar to rise higher than normal. This can lead to serious, long-term problems such as kidney damage, cardiovascular disease and blindness.
How are Randox supporting the battle against the world’s obesity crisis?
Through extensive investment in R&D, we are able to offer cutting-edge diagnostic tests to assess the risk of obesity-related diseases before they occur!
Randox offers the unique adiponectin test to assess the risk of developing T2DM. Low adiponectin levels have also been linked with the risk of developing other pathologies including metabolic syndrome and cardiovascular diseases. The adiponectin test is applicable to both patients with diagnosed clinical obesity, and those deemed to have a ‘healthy’ BMI through a condition known as ‘abdominal obesity’.
This is because while it is widely recognised that people who are overweight or obese are at higher risk of developing T2DM, you don’t have to be overweight to be at risk of developing diabetes. When abdominal visceral fat is stored further underneath the skin and accumulates around major organs, a condition known as abdominal obesity, it greatly increases the risk of developing T2DM. When abdominal visceral fat levels become increased, adipocytes which secrete the protein hormone adiponectin become reduced; this reduces the anti-inflammatory and insulin-sensitising properties of this powerful hormone.
The adiponectin test is available for use on hundreds of clinical biochemistry analysers, and can also be run on our world leading RX series range of clinical chemistry analysers. Find out more here: www.randox.com/obesity/
Our world-renowned quality control products help ensure the accuracy of obesity-related testing!
When diagnosing and monitoring obesity-related complications such as cardiovascular disease (CVD) and T2DM, it is vital that laboratories have a robust quality control system in place to ensure the accuracy and reliability of the results produced. This is especially true considering, 70% of medical decisions are based on a laboratory test result.
It is estimated that over 90% of T2DM is related to obesity. When monitoring diabetes, glycated haemoglobin (HbA1c) levels in the blood provide an indication of average blood glucose levels for the previous 3 months. It is therefore important that the chosen quality control will effectively challenge the test system across the patient reportable range, as an inaccurate result at the cut-off could mean a patient does not receive appropriate diabetes treatment. Our Acusera Liquid HbA1c control provides clinically relevant levels, not only helping to ensure accurate instrument performance but maximising laboratory efficiency. Find out more here: www.randox.com/obesity/
Obesity prevention
Thankfully, for those deemed to be at risk, obesity and related illnesses are largely preventable through engaging in regular physical activity (60 minutes daily recommended for adults), limiting energy intake from total fats and sugars and increasing the consumption of fruit and veg, whole grains and nuts. Knowing your risk allows you to stay in control of your health throughout this festive season!
Further to our clinical lab tests, our Randox Health clinics offer heart health, metabolic health and diabetes health testing as part of our Everyman, Everywoman and Signature packages to identify and assess risk of developing obesity-related diseases. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).
For more information about our clinical diagnostic range of obesity-related products, visit www.randox.com/obesity/
Randox Combating Obesity
Obesity is a condition where a person has abnormal or excessive fat accumulation that presents a serious risk to health. This December, Randox are highlighting the health implications of this potentially deadly condition.
Did you know?
Approximately 8.5% of adults worldwide currently have diabetes
Worldwide obesity has almost tripled between 1975 and 2016, with over 650 million adults and 340 million children being recorded as obese in 2016 alone, highlighting that the prevalence of the condition is rapidly rising. Randox are dedicated to improving health and increasing the awareness and prevention of obesity and its consequences.
The risks and complications of being obese are severe, Obesity will increase an individual’s chances of suffering from several illnesses including musculoskeletal disease, some forms of cancer, cardiovascular disease, diabetes and Osteoarthritis all of which will lower an individual’s standard of living.
Type 2 diabetes is one of the most severe potential consequences of obesity this occurs when a resistance to insulin has been developed due to an elevated level of blood sugar. Some of the effects that diabetes can have on an individual include kidney failure, blindness and amputation. To find out more about the issue check out our blog:
Related Products
Randox has developed the RX series of clinical chemistry analysers or superior semi-automated and fully automated testing. The RX series extensive dedicated test menu goes beyond routine testing and has many unique and high-performance tests available. Our range of tests covers many illnesses that are associated with and stem from obesity.
Diabetes Panel
| Cholesterol | Direct HDL Cholesterol | Glycerol | Ranbut (Hydroxybutyrate) |
| Creatinine Enzymatic | Direct LDL Cholesterol | HbA1c/Hb | Total Protein |
| Creatinine (Jaffe) | Fructosamine | Microalbumin | Triglycerides |
| Cystatin C | Glucose | NEFA (Non-Esterified Fatty Acids) | Urinary Protein |
| Adiponectin
|
Cardiac Panel
| Cholesterol | CRP Full Range(0.3-160mg/l) | Direct LDL Cholesterol | sLDL |
| CK-MB | CRP High Sensitivity | Heart-Type Fatty Acid Binding Protein (H-FABP) | Triglycerides |
| CK-NAC | Digoxin | Lipoprotein(a) | TxB Cardio |
| CRP | Direct HDL Cholesterol | Myoglobin |
Our world leading test menu of high quality reagents guarantees excellence in patient care ensuring unrivalled precision and accuracy reducing costly test re-runs or misdiagnosis and offering complete confidence in results.
The RX series clinical chemistry analysers provide laboratories with a robust and smart solution ensuring you maintain a consistent workflow and can provide accurate results first time, every time. Offering excellent customer support services, our trained engineers are on hand to work with you in preserving the continuity of your operations while maximising the potential of your RX series instrument.
For more information visit: http://www.randox.com/clinical-chemistry-analysers/
Randox supply a range of third party clinical diagnostic reagents to aid in the risk assessment and diagnosis of obesity-related illnesses, and for managing the complications of such illnesses. All reagents are available for use on a range of third party biochemistry analysers. Contact us to request an application for your specific analyser.
Unique tests from Randox
sLDL
- The Randox sLDL is the only automated assay for clinical detection of small-dense LDL (sLDL) on the market. Furthermore, sLDL is a vital cardiac risk marker. Research has shown individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction (MI), even for those whose HDL, LDL, Total Cholesterol and Triglyceride levels are considered ‘normal’. Elevated levels of sLDL are associated with a sedentary lifestyle, a diet high in saturated fat, insulin resistance, pre-diabetes and genetic disposition. Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels reduce the risk of both CVD and MI. Furthermore, the Randox sLDL assay uses the “Denka Seiken” method which produces results in ten minutes.
- For more information visit: http://www.randox.com/sldl-cholesterol/
Lipoprotein(a)
- Lipoprotein(a) is a major independent genetic risk factor for premature CVD and elevated levels can occur in patients with otherwise normal lipid levels. Randox Lipoprotein(a) can therefore provide much needed additional information in relation to a patient’s risk of developing CVD. With our Lipoprotein(a) assay, Randox are breaking the boundaries of cardiology testing and providing laboratories with an opportunity to take their testing beyond the routine and get a more complete picture of patient risk.
- For more information visit: http://www.randox.com/lipoprotein-a/
Cystatin C
- A superior measure of renal function, Cystatin C is extremely sensitive to very small changes in GFR and is therefore capable of detecting early stage kidney dysfunction. Up to 50% of renal function can be lost before significant creatinine elevation occurs. The Randox Cystatin C test provides an accurate method for the determination of Cystatin C in human serum and plasma.
- For more information visit: http://www.randox.com/cystatin-c/
Further testing panels from Randox
Cardiac risk panel
- Apolipoprotein A-I
- Apolipoprotein A-II
- Apolipoprotein B
- Apolipoprotein C-II
- Apolipoprotein C-III
- Apolipoprotein E
- Cholesterol (sLDL)
- Cholesterol (HDL)
- Cholesterol (LDL)
- Cholesterol (Total)
- Cholesterol (HDL3)
- Lipoprotein (a)
- High sensitivity CRP
- Homocysteine
- Triglycerides
Diabetes diagnosis and monitoring panel
- Fructosamine
- Glucose
- HbA1c
Diabetes complications monitoring
- Albumin
- β₂Microglobulin
- Cystatin C
- Creatinine (Enzymatic)
- Creatinine (JAFFE)
- D-3-Hydroxybutyrate (Ranbut)
- Microalbumin
- Non-Esterified Fatty Acids (NEFA)
Learn more about our range of analyser applications, available or alternatively contact us to request an application for your specific analyser at Reagents@randox.com
When diagnosing and monitoring obesity-related complications such as cardiovascular disease (CVD) and T2DM, it is vital that laboratories have a robust Quality Control (QC) system in place to ensure the accuracy and reliability of the results produced. As a world leading manufacturer of QC solutions including Third Party Controls and External Quality Assessment (EQA), our extensive product portfolio is designed to help reduce costs and time without compromising on quality.
Diabetes
Liquid HbA1c Control
- Liquid ready-to-use format ideal for use in the lab or at the POCWhole blood sample matrix commutable with that of the patient sample
- Assayed control with values available for HPLC
- Convenient bi-level pack accurately covering the patient reportable range
- Open vial stability of 30 days ultimately helping to reduce waste and costs
- For more information visit: http://www.randox.com/liquid-hba1c-quality-control/
Glycated Hemoglobin EQA Programme
- Monthly analysis ensuring early identification of test system errors
- Maximised peer groups for comparative performance assessment
- Reports available within 72 hours allowing corrective action to be taken immediately
- User-friendly reports delivering at-a-glance performance assessment
- For more information visit: http://www.randox.com/hba1c-eqa/
CVD risk
- Lipid Control
- Covers the complete lipid profile
- True third party control ensuring unbiased performance assessment with any instrument or method
- Manufactured from 100% human serum ensuring a matrix commutable with the patient sample
- Free from Sodium Azide which can interfere with direct clearance methods of HDL and LDL Cholesterol
- Three clinically significant levels available covering low, borderline and high risk levels of HDL and LDL Cholesterol
- For more information visit: http://www.randox.com/lipid-quality-control/
Lipid EQA Programme
- Covers the complete lipid profile with a choice of reporting just three parameters at a reduced cost
- Monthly analysis ensuring early identification of test system errors
- Maximised peer groups for comparative performance assessment
- Reports available within 72 hours allowing corrective action to be taken immediately
- User-friendly reports delivering at-a-glance performance assessment
- For more information visit: http://www.randox.com/lipids-eqa/
Our Randox Health clinics offer heart health, metabolic health and diabetes health testing as part of our Everyman, Everywoman and Signature packages to identify and assess risk of developing obesity-related diseases. Our clinics utilise the same cutting-edge tests and quality control that we have available to clinical laboratories globally, as well as our patented Biochip Array Technology (BAT).
For more information visit: https://www.randoxhealth.com/
Randox Reagents celebrate World Kidney Day 2017
On 9 March 2017, Randox Reagents are celebrating World Kidney Day! World Kidney Day is a global campaign aimed at raising awareness of the importance of our kidneys to our overall health. It aims to reduce the frequency and impact of kidney disease and its associated health problems worldwide.
This year, the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviours an affordable option.
With this in mind, throughout the week we have been sharing on social media some interesting facts on diagnostic tests which can help aid an early risk assessment of kidney disease in obese patients, allowing preventative action to be taken before any serious damage occurs. The tests of focus this week included cystatin C, adiponectin and microalbumin…
Cystatin C
The creatinine test is routinely run for patients who are suspected for deteriorating kidney function, however this test has limitations. Cystatin C is an alternative test, and is particularly useful in patients where creatinine measurements are not suitable e.g. individuals who are obese, malnourished, have liver cirrhosis or reduced muscle mass. Importantly, unlike creatinine, cystatin C does not have a ‘blind area’ – up to 50% of kidney function can be lost before significant creatinine elevation occurs. Cystatin C is extremely sensitive to very small changes in kidney function and is therefore capable of detecting early stage kidney dysfunction. The cystatin C test therefore allows preventative measures to be taken much earlier and before significant kidney function decline.
Adiponectin
There is substantial evidence that excess visceral fat is the main driving force for almost all of the disorders associated with the metabolic syndrome, including CKD.1,2 The adiponectin test from Randox can accurately assess levels of abdominal visceral fat, independent of age, race or fitness level.3,4 Assessing adiponectin, and therefore visceral fat levels, can help assess risk of CKD, as well as a range of other illnesses such as pre-diabetes, CVD and various cancers.
Microalbumin
The microalbumin test detects very low levels of a blood protein called albumin, in urine. The detection of albumin in urine can be an indicator of kidney injury and can result in irreversible damage if left untreated. Low albumin concentrations in the urine are the earliest marker of kidney damage and therefore enable preventative measures to be taken. Microalbumin testing can identify individuals with diabetic nephropathy approximately 5-10 years earlier than proteinuria tests helping reduce the frequency of end stage renal disease.
Both World Kidney Day and Randox are working towards improving healthcare worldwide. With continuous investment in R&D, Randox are helping with the risk assessment and earliest detection of renal function problems. By assessing one’s risk of kidney problems (with the adiponectin test), it can give patients (obese and other) the tools to prevent kidney problems further on down the line. With early diagnosis (through the cystatin C and microalbumin tests) it will be possible to keep kidney problems from getting worse, therefore lowering the number of those diagnosed with CKD worldwide.
For health professionals
If you are a clinician or lab interested in running renal function assays, Randox offers a large range of high quality routine and niche assays including: Cystatin C, Creatinine Enzymatic and Jaffe, Microalbumin, Urinary Protein, Urea, Sodium, Potassium, Albumin, Ammonia, β2- Microglobulin, Calcium, Chloride, Glucose, HbA1c, IgG, LDH, Magnesium, Phosphorus (Inorganic), and Uric Acid. These can be run on most automated biochemistry analysers.
For more information, download our Diabetes Brochure or email reagents@randox.com.
References
- Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic renal disease?Adv Ren Replace Ther. 2004;11(1):41–54. [PubMed]
- Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update.Physiol Rev. 2013;93(1):359–404. [PubMed]
- Matsuzawa, Y. The role of fat topology in the risk of disease. Int J Obes. 2008;32:s83-s92.
- Frederiksen, L., Nielsen, T. L., Wraae, K., Hagen, C., Frystyk, J., Flyvbjerg, A., Brixen, K. and Andersen, M. Subcutaneous Rather than Visceral Adipose Tissue Is Associated with Adiponectin Levels and Insulin Resistance in Young Men. JCEM, (2009) 94 (10): 4010-4015.
Further reading:
